Lataa...
An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function
Hepatitis C virus (HCV) infection affects roughly 170 million people worldwide. Sofosbuvir/Ledipasvir (Sof/Led) is a new once daily direct acting antiviral combination pill that was approved in October 2014 for use in patients with HCV genotype 1 infection. Coadministration of Sof/Led is studied onl...
Tallennettuna:
| Julkaisussa: | Case Rep Med |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Hindawi Publishing Corporation
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5011228/ https://ncbi.nlm.nih.gov/pubmed/27635145 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/3191089 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|